GLP-1TRZ

GLP-1TRZ is the PrimeTime BioLabs product name for a research peptide representing tirzepatide, a 39-amino-acid synthetic peptide. The name change does not alter the underlying research material — it identifies the same tirzepatide-based product previously listed under its scientific name, now presented under PrimeTime's own product naming convention. Each unit ships as a lyophilized powder in a sealed, light-protected vial. A printed lot number on the vial matches the batch number on the Certificate of Analysis, giving researchers a direct way to confirm that the documentation on file corresponds to the specific unit they received. This traceability matters most when a lab is comparing results across shipments or archiving records for internal quality systems, since a mismatched lot number would make any purity or identity data meaningless for that particular vial. Tirzepatide's structure is based on the native GIP sequence, with amino acid substitutions that stabilize the peptide against enzymatic degradation and a fatty-acid side chain conjugated through a linker at a lysine residue. That combination is what allows tirzepatide to engage two related but distinct incretin receptors rather than one, which is the structural basis for the dual-agonist research interest discussed in the following tab. Researchers who are already familiar with tirzepatide from clinical or pharmaceutical literature should note that PrimeTime's GLP-1TRZ is supplied strictly as a research material, in a research-grade format, for laboratory use. It is not formulated, packaged, or labeled as a drug product, and no clinical dosing information accompanies it. Reference material describing the peptide's handling is included with each order for laboratory use; PrimeTime does not publish administration, injection, or human-use instructions of any kind, on this page or elsewhere. Researchers who require a different pack size should check the Shop for other tirzepatide-based listings or contact PrimeTime directly.

GLP-1TRZ represents tirzepatide, a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-receptor activity distinguishes it from single-target GLP-1 receptor agonists such as semaglutide, and it is the primary reason tirzepatide has drawn sustained interest in incretin research over the past several years. At the molecular level, tirzepatide is a 39-amino-acid peptide with the molecular formula C₂₂₅H₃₄₈N₄₈O₆₈ and a molecular weight of approximately 4,813 g/mol (PubChem CID 156588324; CAS 2023788-19-2). Its backbone is derived from the native GIP sequence, with two amino acid substitutions that reduce its susceptibility to DPP-4 enzymatic breakdown, and a C20 fatty di-acid chain attached through a linker at a lysine residue that extends its half-life in biological systems. These structural features are what allow a single molecule to engage two related incretin receptor pathways instead of one. In research contexts, this dual-agonist mechanism has been used to study how combined GIP and GLP-1 receptor engagement compares to GLP-1-only pathway activation — for example, in models examining insulin secretion, gastric emptying, and appetite-related signaling. Researchers investigating incretin biology have also used dual agonists like tirzepatide to probe questions about receptor cross-talk and downstream signaling that a selective GLP-1 agonist cannot address on its own. It's worth being precise about what this research context does and does not establish. Peer-reviewed literature and FDA labeling describe tirzepatide's receptor pharmacology at the molecular level, and separately describe clinical outcomes observed in trials of FDA-approved tirzepatide medicines. Neither of those bodies of evidence says anything about PrimeTime's specific research material — its purity, its identity, or its suitability for any particular experimental protocol. That determination rests on the batch-specific analytical testing described in the next tab, not on the general scientific literature about the molecule. GLP-1TRZ is supplied for laboratory research applications such as receptor-binding assays, peptide identity and stability studies, and analytical method development. It is not supplied, described, or intended for any diagnostic, therapeutic, or human- or animal-use application. Source: Tirzepatide molecular data — PubChem CID 156588324, National Center for Biotechnology Information (NCBI).

Every batch of GLP-1TRZ undergoes third-party HPLC and mass spectrometry testing before it ships. HPLC analysis is used to quantify purity by measuring how much of the sample consists of the intended peptide versus synthesis byproducts or degradation products. Mass spectrometry is used separately to confirm identity — verifying that the molecule present actually matches tirzepatide's expected mass, rather than a related or incorrectly synthesized peptide. The current batch of GLP-1TRZ carries a purity result of 99.9%, confirmed by the issuing laboratory and documented on a batch-specific Certificate of Analysis (COA). The COA lists the batch number, the purity result, and the date of analysis, and it is written to correspond to a specific lot rather than to the product line in general. Matching the lot number on your vial to the lot number on the COA is the only reliable way to confirm that a given certificate applies to the unit you actually received; a COA for a different batch, however similar the reported numbers look, does not verify the vial in hand. It's important to be clear about what this testing does and does not demonstrate. A high purity result confirms that the sample is chemically clean relative to the analytical method used — it does not establish biological activity, stability under every storage condition, or suitability for a specific research protocol. Identity testing by mass spectrometry confirms that the peptide matches tirzepatide's expected molecular signature; it does not constitute clinical validation, and it does not mean the material has been evaluated for any therapeutic, diagnostic, or human-use purpose. A Certificate of Analysis is a laboratory quality document, not a regulatory approval, and it should not be read as either. Documentation from PrimeTime's own analytical testing is separate from — and should not be confused with — the general scientific literature on tirzepatide as a molecule, or the clinical trial evidence supporting FDA-approved tirzepatide medicines. Each of those three categories of evidence answers a different question, and none of them substitutes for the others.

GLP-1TRZ is sold strictly for laboratory and research use. It is not a drug, food, dietary supplement, or cosmetic product, has not been evaluated by the FDA, and is not intended for human or animal consumption, diagnosis, or treatment of any kind. Tirzepatide is the active ingredient in FDA-approved pharmaceutical products marketed under other brand names for the treatment of type 2 diabetes and for chronic weight management. GLP-1TRZ is not one of those approved medicines, is not manufactured to pharmaceutical drug-product standards, and is not represented as equivalent, interchangeable, or substitutable for any approved medicine. The existence of clinical evidence supporting an approved tirzepatide medicine does not extend to, or validate, PrimeTime's research material. This page does not provide, and PrimeTime does not publish, dosing information, administration instructions, injection guidance, reconstitution protocols, or treatment schedules of any kind for GLP-1TRZ, on this page or elsewhere on the site. Researchers ordering this product are responsible for ensuring their use complies with all applicable institutional, state, and federal requirements governing research materials. Any handling reference material included with a shipment is intended solely to support safe laboratory handling of a research chemical — it is not medical, veterinary, or human-use guidance, and should not be treated as such.